A detailed history of Morgan Stanley transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 289,157 shares of KROS stock, worth $13.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
289,157
Previous 925,388 68.75%
Holding current value
$13.2 Million
Previous $36.8 Million 47.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$41.26 - $70.48 $26.3 Million - $44.8 Million
-636,231 Reduced 68.75%
289,157 $19.1 Million
Q4 2023

Feb 13, 2024

BUY
$27.12 - $41.05 $12.9 Million - $19.6 Million
476,687 Added 106.24%
925,388 $36.8 Million
Q3 2023

Nov 15, 2023

BUY
$31.57 - $43.02 $12.6 Million - $17.2 Million
398,903 Added 801.04%
448,701 $14.3 Million
Q2 2023

Aug 14, 2023

SELL
$37.26 - $51.01 $3.4 Million - $4.65 Million
-91,172 Reduced 64.67%
49,798 $2 Million
Q1 2023

May 15, 2023

SELL
$41.44 - $59.32 $82,507 - $118,106
-1,991 Reduced 1.39%
140,970 $6.02 Million
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $3.21 Million - $4.22 Million
81,440 Added 132.38%
142,961 $6.86 Million
Q3 2022

Nov 14, 2022

SELL
$27.8 - $40.12 $1.62 Million - $2.34 Million
-58,277 Reduced 48.65%
61,521 $2.31 Million
Q2 2022

Oct 27, 2022

BUY
$26.03 - $67.04 $1.77 Million - $4.56 Million
67,970 Added 131.15%
119,798 $3.31 Million
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $1.77 Million - $4.56 Million
67,970 Added 131.15%
119,798 $3.31 Million
Q1 2022

Oct 27, 2022

SELL
$42.12 - $59.36 $2.86 Million - $4.03 Million
-67,970 Reduced 56.74%
51,828 $2.82 Million
Q1 2022

May 13, 2022

BUY
$42.12 - $59.36 $1.88 Million - $2.65 Million
44,687 Added 625.78%
51,828 $2.82 Million
Q4 2021

Feb 14, 2022

SELL
$36.95 - $62.89 $2.7 Million - $4.6 Million
-73,071 Reduced 91.1%
7,141 $417,000
Q3 2021

Nov 15, 2021

BUY
$29.27 - $43.71 $2.35 Million - $3.51 Million
80,212 New
80,212 $3.17 Million

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.